New therapeutic targets for the management of moderate-severe psoriasis

Abstract

The field of moderate-severe psoriasis is experiencing a real therapeutic revolution in recent years with the appearance of new molecules that present more selective pathophysiological targets. The incorporation of biosimilar drugs with less clinical development than the original brands may result in the incorporation of new molecules with better levels of efficacy and safety being relegated to the background. In the present review, we review the main anti-IL-17, anti-IL-23, and JAKi drugs that have been incorporated and will soon be incorporated into our therapeutic arsenal, making special mention of their efficacy, safety, and persistence characteristics as deduced from the main pivotal clinical trials and series of real clinical practice.

Keywords

• Psoriasis. JAK inhibitor. Interleukin 23 blockers. Interleukin 17 blockers.